Drug Makers In India Move To Lifestyle Drugs For Income
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers are reshaping portfolios in an effort to gain a greater share of lifestyle medicine sales. Among them is Alembic, whose emphasis has been on antibiotic and other acute-therapy drugs, but now moving into an emphasis on cancer, cardiovascular and diabetes drugs. Alembic acquired a non-oncology portfolio from Dabur Pharma last year to give it an entry into that market. Indian drug makers see lifestyle drugs as growing from the current 14 percent to 17 percent of the market by 2010. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.